To complement these computational studies, experimental validation will be conducted, including in vitro EGFR kinase inhibition assays, cell viability/proliferation studies in EGFR-overexpressing breast cancer cell lines, Ames test for mutagenicity, hERG patch-clamp assays to assess cardiotoxicity, and microsomal stability studies to evaluate metabolic stability. The gene discussed is KCNH2; the disease is breast carcinoma.